相关实验视频

Updated: Jul 18, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

在接受内分泌治疗的乳腺癌患者中,症状概况和相关因素:潜在概况分析

Feng Jing¹, Zheng Zhu, Jiajia Qiu

¹Author Affiliations: School of Nursing and Centre for Evidence-based Nursing: A Joanna Briggs Institute Centre of Excellence, Fudan University (Ms Feng Jing, Mr Zheng Zhu, Ms Lei Xu, and Ms Weijie Xing); Department of Nursing Administration, Shanghai Cancer Center, Fudan University (Ms Jiajia Qiu); Department of Oncology, Shanghai Medical College, Fudan University (Ms Jiajia Qiu and Dr Lichen Tang); and Department of Breast Surgery, Shanghai Cancer Center, Fudan University (Dr Lichen Tang), Shanghai, China.

|August 22, 2023

概括

了解乳腺癌内分泌治疗中的患者变异性是关键. 年轻的患者,那些自付,使用芳酶抑制剂或有化疗史的患者,面临更高的症状负担.

科学领域:

在瘤学瘤学.
内分泌学在内分泌学.
患者护理患者护理

背景情况:

在接受内分泌治疗的乳腺癌患者中,症状体验的个体间变异性需要进一步调查.
社会人口统计学和临床因素对这一群体症状概况的影响尚不清楚.

研究的目的:

在接受内分泌治疗的乳腺癌患者中识别不同的症状概况.
确定与属于这些症状子组相关的社会人口统计和临床特征.

主要方法:

一项采用问卷的横截面研究,包括癌症治疗功能评估-内分泌子标尺.
隐形形状分析,单变分析和多项逻辑回归被用来分析症状形状和个体间的变异性.

主要成果:

确定了三个不同的症状概况:"所有高" (9.8%),"所有中度但高的性症状" (25.4%),和"所有低" (64.8%).
影响子组成员的因素包括年龄,体重指数,医疗费用支付来源,内分泌疗法类型和以前的乳腺癌治疗史.

结论:

人口和临床特征与乳腺癌患者内分泌治疗相关的症状概况有关.
年龄较小,自费医疗费用,使用芳酶抑制剂,先前的化疗和更高的BMI与增加的症状负担有关.

更多相关视频

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...